Previous Article | Next Article 
Journal of Virology, October 2001, p. 9723-9730, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9723-9730.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Efficient Virus Extinction by Combinations of a
Mutagen and Antiviral Inhibitors
Nonia
Pariente,1
Saleta
Sierra,1,
Pedro R.
Lowenstein,2 and
Esteban
Domingo1,*
Centro de Biología Molecular
"Severo Ochoa," Universidad Autónoma de Madrid,
Cantoblanco, 28049 Madrid, Spain,1 and
Molecular Medicine Unit, Department of Medicine, University
of Manchester, Manchester M13 9PT, United Kingdom2
Received 25 April 2001/Accepted 23 July 2001
 |
ABSTRACT |
The effect of combinations of the mutagenic base analog
5-fluorouracil (FU) and the antiviral inhibitors guanidine
hydrochloride (G) and heparin (H) on the infectivity of foot-and-mouth
disease virus (FMDV) in cell culture has been investigated. Related
FMDV clones differing up to 106-fold in relative fitness in
BHK-21 cells have been compared. Systematic extinction of intermediate
fitness virus was attained with a combination of FU and G but not with
the mutagen or the inhibitor alone. Systematic extinction of
high-fitness FMDV required the combination of FU, G, and H. FMDV
showing high relative fitness in BHK-21 cells but decreased replicative
ability in CHO cells behaved as a low-fitness virus with regard to
extinction mutagenesis in CHO cells. This confirms that relative
fitness, rather than a specific genomic sequence, determines the FMDV
response to enhanced mutagenesis. Mutant spectrum analysis of several
genomic regions from a preextinction population showed a statistically
significant increase in the number of mutations compared with virus
passaged in parallel in the absence of FU and inhibitors. Also, in a
preextinction population the types of mutations that can be attributed
to the mutagenic action of FU were significantly more frequent than
other mutation types. The results suggest that combinations of
mutagenic agents and antiviral inhibitors can effectively drive
high-fitness virus into extinction.
 |
INTRODUCTION |
An increase in the mutation rate
during replication of RNA viruses can result in a decrease of viral
infectivity and occasional virus extinction (11, 34, 39, 40,
60). Studies with the important animal pathogen foot-and-mouth
disease virus (FMDV)
a member of the Picornaviridae family
(53, 63)
have shown that a small replicative population
size and low viral fitness favored virus extinction (60).
This was documented with single and multiple passages of FMDVs
differing up to 106-fold in relative fitness in the absence
or presence of the mutagenic base analogs 5-fluorourocil (FU) or
5-azacytidine, individually or in combination (59, 60).
Mutagenic treatments resulted in occasional, not systematic, viral
extinction, while parallel passages in the absence of mutagens never
led to loss of infectivity, no matter how low the initial viral
population size and fitness were (59, 60). These results
suggested the possibility that a combination of an antiviral inhibitor,
to reduce the replicative load of virus, and a mutagenic agent could be
more effective in producing viral extinction than a mutagenic agent
used in isolation. To test this possibility we have studied the effect
of the mutagenic base analog FU and the antiviral inhibitors guanidine
hydrochloride (G) and heparin (H) on the infectivity of FMDV clones and
populations depicting a wide range of relative fitness values. FU has
been shown to be mutagenic for a number of RNA viruses (6, 20, 31, 34, 51, 71), including FMDV (59, 60). G at
millimolar concentrations blocks the replication of picornaviruses
(5, 7, 15, 49, 52, 55), arboviruses (27), and
several plant viruses (13, 67). In poliovirus, the target
of G is the ATPase activity of nonstructural protein 2C
(49), a protein involved in viral replication and
encapsidation. In FMDV, amino acid substitutions at 2C have also been
associated with resistance to G (56). Heparins are
sulfated polysaccharides (9) which bind FMDV when the
virus has been passaged in cell culture and has adapted to using
heparan sulfate (HS) as a receptor (2, 35, 54). Adaptation
to use of HS as a receptor has been associated with substitutions which
lead to positively charged amino acids at exposed positions of the
capsid (2, 54).
Here we report that high-frequency extinctions of FMDV of low and
intermediate fitness values can be achieved with a combination of FU
and G but not with either drug alone. Extinction of high-fitness FMDV
populations required a triple combination of G and H together with FU.
Mutation frequencies in the mutant spectrum of three genomic regions of
a preextinction population obtained by the combined action of an
inhibitor and a mutagen were compared to values in genomes passaged in
standard conditions and also to values previously determined for FMDV
populations subjected to one or multiple passages in the presence of FU
(60). We found that mutation frequencies increased up to
fourfold. There was also a statistically significant increase in the
number of mutations in preextinction populations with respect to
control populations, and the frequency of mutation types that can be
attributed to the mutagenic action of FU was significantly higher than
the frequency of other types of mutations.
 |
MATERIALS AND METHODS |
Cells and viruses.
The origins of baby hamster kidney 21 cells (BHK-21) and Chinese hamster ovary cells (CHO) have been
previously described (3, 18, 25, 62). Both cell types were
grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco)
supplemented with nonessential amino acids (Gibco), 50 mg of gentamicin
(Sigma)/ml, and 5% fetal calf serum (Gibco).
FMDV C-S8c1 is a plaque-purified derivative of the European serotype C
natural isolate C1 Santa Pau-Spain 70 (62).
MARLS is a monoclonal antibody escape mutant obtained from FMDV C-S8c1 passaged 213 times in BHK-21 cells (C-S8c1p213) (3). MARLS includes the substitution L-144
S at antigenic site A, located within
the G-H loop of the capsid protein VP1 (43, 44). In BHK-21
cells, the replicative fitness of MARLS is about 130-fold higher than
that of C-S8c1 (59). In CHO cells the replicative fitness
of MARLS is lower than in BHK-21 cells, as indicated by a delayed
kinetics of viral production and a 10-fold reduction in the viral titer
at the point of complete cytopathic effect. No ranking of the
relative fitnesses of FMDV mutants has been established with CHO cells.
Clones H
1 to
5 are a series of low-fitness
subclones from the clone H5 (derived from C-S8c1p113 [23]) after 95 plaque-to-plaque transfers in BHK-21 cells (C. Escarmís et al.,
unpublished results). Relative fitness of the H
subclones was estimated on the basis of the number of infectious
progeny produced per plaque (23): their relative fitness
is about 104-fold lower than that of C-S8c1 virus. A good
correspondence between relative fitness values obtained in growth
competition experiments and those estimated on the basis of infectious
progeny production has been previously documented with several FMDV
clones and populations (23); Escarmís et al.,
unpublished results).
Procedures for infection of BHK-21 cell monolayers with FMDV in liquid
medium and for plaque assays in semisolid agar medium
have been
previously described (
3,
18,
62). The standard
viral
production assay with BHK-21 cells consisted of the infection
of 9 × 10
5 cells with FMDV at a multiplicity of infection of
approximately
0.05 PFU per cell. Further passages were carried out with
0.1
ml of the supernatant of the previous infection. For assays with
CHO cells, 9 × 10
5 cells were infected with FMDV
MARLS at a multiplicity of infection
of 1 PFU per cell in the first
passage, and the following passages
were carried out with 0.1 ml of the
supernatant of the previous
passage. Except for preextinction
populations, the multiplicity
of infection of successive passages
ranged from 0.001 to 1 PFU
per cell, and the value for each individual
infection can be calculated
from the titers shown in the corresponding
figures. To control
for the absence of viral contamination, parallel
passages of supernatants
of mock-infected cells were carried out
throughout the experiments,
with no evidence of infectivity or
cytopathology in the cultures.
Viruses were titrated at every passage,
on BHK-21 cell monolayers,
in
triplicate.
Mutagenic and antiviral treatments.
To prepare culture
medium containing FU (Sigma), the appropriate amount of analog was
dissolved in DMEM to yield a 2.5-mg/ml solution, which was diluted in
DMEM as needed for the experiments. To prepare medium containing G
(Sigma), the appropriate amount was dissolved in DMEM to yield a 4 mM
solution (0.38 mg/ml). To prepare medium containing a mixture of both
FU and G, the appropriate amount of G was added to DMEM containing FU
(200 µg/ml) to yield FUG, a solution containing FU (200 µg/ml) and
G (4 mM). H (Heparin sodium salt; Sigma) was dissolved in water and
diluted in DMEM or FUG (to yield FUGH, a solution containing FU [200
µg/ml], G [4 mM], and H [1 mg/ml]) as needed for the
experiments. All solutions were sterilized by filtration. Media were
supplemented with 2% fetal calf serum and stored at 4°C for a
maximum of 14 days. The effect of FU, inhibitors, or their combination
on cell viability was monitored by trypan blue exclusion as described
previously (60). Before counting, cells were washed with
DMEM, detached by trypsin treatment, and resuspended in DMEM
supplemented with 2% fetal calf serum. Viable BHK-21 cells comprised
at least 20% of the total (Fig. 1),
under the doses and times of exposure used for the experiments. CHO
cells were more resistant than BHK-21 cells to the treatments, and
after exposure to FUG, approximately 80% of the cells were viable (N. Pariente et al., unpublished data).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
BHK-21 cell viability in the presence of FU, G, and H,
alone or in combination. The origin of BHK-21 cells and FMDV C-S8c1, as
well as procedures for cell growth, antiviral treatment, quantification
of cell viability, and infections with FMDV, are detailed in Materials
and Methods. Percent cell viabilities (trypan blue exclusion) were
calculated relative to those in parallel, untreated cell cultures,
counting 300 to 700 cells per sample. Hours of exposure refers to the
time elapsed between the addition of the mutagen or antiviral agent to
cells and the determination of cell viability. Standard deviations (not
included in the plots) never exceeded 20%.
|
|
In order to establish whether the 20% of BHK-21 cells that were left
after 37 h of exposure to FUGH were able to sustain FMDV
replication,
cell monolayers that had been preincubated for 13
h with FU and
for 24 h with FUGH were washed with DMEM and incubated
for 2 h with DMEM supplemented with 2% fetal calf serum. Then,
the cells
were infected either with MARLS, at a multiplicity of
infection of
about 10 PFU per cell, or with the low-fitness H
clone, at about 0.005 PFU per cell. Parallel infections of confluent
BHK-21 cell monolayers were carried out as a control. The titer
of
MARLS attained in treated cells was 1 × 10
7 PFU/ml,
versus 4 × 10
8 PFU/ml in untreated cells. In the case
of the low-fitness H
clone, titers were 7 × 10
4 PFU/ml and 1 × 10
7 PFU/ml,
respectively. This implies that cytotoxicity cannot account
for viral
extinction, since even a very low-fitness virus can
carry out its life
cycle in treated cells in infections started
with very low numbers of
infectious
units.
Viral infections in the presence of FU, inhibitors, or their
combination.
Different standard single infections were carried out
in parallel. (i) In control infections (absence of mutagen and
inhibitors), confluent cell monolayers were infected with FMDV
(adsorption for 45 min at 37°C), washed for 1 min with 0.1 M
phosphate buffer (pH 6.0) (to inactivate unadsorbed virions), and
washed again extensively with DMEM. The infection was allowed to
proceed in DMEM supplemented with 2% fetal calf serum. (ii) For
infections in the presence of FU, confluent cell monolayers were
pretreated for 13 h with 200 µg of FU/ml and then washed with
DMEM; the procedure was done as for the control infections, and the
infection was allowed to proceed in the presence of the same
concentration of FU. (iii) For infections in the presence of G, no
pretreatment of the cell monolayer was performed; after addition of
FMDV and washing of the cell monolayers, the infection was allowed to
proceed in the presence of 4 mM G. (iv) For infections in FUG,
confluent cell monolayers were pretreated for 13 h with 200 µg of
FU/ml and then washed with DMEM. After virus adsorption and washing of
cell monolayers, the infection proceeded in the presence of FUG. (v)
For infections in H, no pretreatment of the cell monolayer was
performed; FMDVs were preincubated with 1 mg of H/ml for 30 min at room
temperature. After inoculation and washing of the cell monolayers, the
infection was allowed to proceed in the presence of 1 mg of H/ml. (vi)
For infections in the presence of FUGH, confluent cell monolayers were
pretreated for 13 h with 200 µg of FU/ml and then washed with
DMEM. Viruses were preincubated with 1 mg of H/ml for 30 min at room
temperature. After virus adsorption and washing of the cell monolayers,
the infection proceeded in the presence of FUGH. All infections were
allowed to continue for approximately 24 h.
For serial passage of virus, 0.1 ml of cell culture supernatant from
the previous infection was used to infect a cell monolayer
pretreated
with a mutagen as described above for the standard
single infections.
Virus was titrated after each passage. When
no cytopathology was
observed, at least three serial blind passages
using undiluted cell
culture supernatant, in the absence of mutagen
and antiviral agents,
were carried out prior to viral detection
tests. Viral extinction is
defined on the basis of two criteria,
as previously described
(
60): absence of infectivity in the
cell culture
supernatant after the last blind passage and no amplification
of viral
genomic regions by reverse transcription and PCR amplification.
Populations passaged in the presence of a mutagen or antiviral
agents
are indicated with the abbreviation of the culture medium
used,
followed by the passage number (e.g., C-S8c1FUGp1 is C-S8c1
passaged
once in the presence of a mixture of FU and
G).
cDNA synthesis, PCR amplification, and nucleotide
sequencing.
Viral RNA was extracted as previously described
(60) using 150 µl of culture medium; for preextinction
populations (virus in the passage prior to extinction), the volume used
was 1 ml due to the low viral load present in these samples. cDNA
synthesis and PCR amplification (reverse transcription-PCR [RT-PCR])
were performed as previously described (23). In all cases
cDNA synthesis was carried out using avian myeloblastosis virus reverse
transcriptase (Promega). Amplification was performed with
Taq polymerase (Perkin-Elmer) for determination of the
consensus sequences and for the extinction test. Amplifications
intended for molecular cloning and nucleotide sequencing of individual
clones were carried out with the Expand High Fidelity PCR System
(Roche) (4). To ensure an excess of template molecules for
amplification, only the samples for which RT-PCR amplification of 1/10
of the initial RNA template was also positive were used for molecular
cloning of the cDNA. Three FMDV genomic regions were subjected to
RT-PCR amplification: residues 3193 to 3869 (spanning the VP1-coding
region), residues 4280 to 5349 (spanning the 2C-coding region), and
residues 6609 to 8035 (spanning the entire 3D [polymerase]-coding
region). Numbering of FMDV genomic nucleotides is that used in
reference 65. The oligonucleotide primers used to amplify
the VP1- and 3D-coding regions have been previously described
(60). The following primers were used for 2C
amplification: 5'-TCGGAGCTCCGATTCTGTTGGCCGGGTTG-3', termed 2BR3SacI (sense, 5' position 4253), and
5'-AAAGAATTCAATTGCTGCCTCGTGTTG-3', termed
3AD4EcoRI (antisense, 5' position 5376); they include restriction enzyme sites for SacI and EcoRI, respectively
(underlined). Amplified cDNAs coding for VP1, 2C, and 3D were digested
with the appropriate restriction enzymes, ligated to plasmid pGEM-4Z
(Promega) previously digested with the same restriction enzymes, and
cloned into Escherichia coli DH5
as described previously
(60). DNA from bacterial colonies was obtained by direct
PCR amplification from colony lysates using the commercial primers SP6
and T7 (Promega), which are complementary to positions flanking the
polylinker site of pGEM-4Z. Nucleotide sequences were determined using
the Big Dye Terminator Cycle Sequencing kit (ABI Prism; Perkin-Elmer)
and the automated sequencer ABI373. Each mutation was confirmed by two
independent sequencing assays using primers of different orientation.
Sequences were analyzed with the DNA Star 4.0, Genedoc, and GCG package programs.
The heterogeneity of the mutant spectrum of viral quasispecies was
quantitated by use of the mutation frequency and normalized
Shannon
entropy (Sn) (
68). Mutation frequency is the number
of
different mutations found relative to the number of nucleotides
sequenced; it is calculated by dividing the number of different
mutations found in a set of genomes (compared to the consensus
nucleotide sequence of the same set) by the total number of nucleotides
sequenced (
16,
21). Sn is a measure of the proportion of
identical
sequences in a mutant distribution. The possible values of
the
Sn range from zero (when all genomes are identical) to one (when
all genomes differ from one another) (
60,
68).
 |
RESULTS |
Systematic extinction of C-S8c1 by a combination of FU and G.
G at a concentration of 4 mM in the culture medium causes a 10- to
102-fold reduction in the production of FMDV C-S8c1 with no
significant effect on BHK-21 cell viability. The combination of 200 µg of FU/ml and 4 mM G (FUG) resulted in a decrease of cell viability to about 40% of that of the untreated cells (Fig. 1). To test whether
FUG was more effective than either FU or G alone in inhibiting viral
production, FMDV MARLS, C-S8c1, and five low-fitness subclones derived
from H
were used to infect BHK-21 cells in the
absence or presence of FU, G, or FUG. The FMDVs used differed up to
106-fold in relative fitness value (see Materials and
Methods). The results (Fig. 2) show that
FUG led to reductions in viral production that were 102- to
103-fold larger than those observed in the presence of FU
or G alone. Yields of the subclones H
3,
H
4 and H
5 in the presence of
FU were undetectable, but virus reemerged after one passage. However,
extinction of the subclones H
1 to
H
5 was observed in all cases in one passage in the
presence of FUG.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of viral fitness on the decrease of infectivity
in a single round of infection in the absence or presence of FU, G, or
the mixture of both (FUG). FMDV MARLS, C-S8c1, and H
clones are described in Materials and Methods. Empty columns indicate
viral production in the absence of mutagen or antiviral agent; gray
columns indicate viral production in the presence of 200 µg of FU/ml;
striped gray columns indicate viral production in the presence of 4 mM
G; and black columns show viral production in the presence of FUG. In
this experiment 9 × 105 BHK-21 cells were infected
with 5 × 104 PFU of virus. Extinction of the five
H FUGp1 clones was confirmed by three
additional blind passages, in the absence of mutagen and inhibitor with
no evidence of infectivity, and no RT-PCR-amplifiable material in the
supernatant of the third passage. Yields of H 3,
H 4, and H 5 clones in the
presence of FU were undetectable (<10 PFU/ml), but virus reemerged
after one blind passage in the absence of the mutagen. However, these
clones were extinguished upon a second passage in the presence of FU.
Titrations were done in triplicate, and standard deviations are
indicated. Procedures for chemical mutagenesis, antiviral treatment,
and determination of viral infectivity are described in Materials and
Methods.
|
|
Previous results showed that serial passage of FMDV C-S8c1 in the
presence of FU resulted in occasional, not systematic, extinction
of
the virus (
60). To evaluate the frequency of extinctions
of C-S8c1 in the presence of FUG, serial passages were carried
out as
detailed in Materials and Methods. Extinction of C-S8c1
was observed at
passage 2 in the presence of FUG but not in the
presence of FU or G
alone (Fig.
3). To test the robustness of
C-S8c1 extinction under these conditions, 46 replicates of an
infection
of 3 × 10
5 BHK-21 cells with 10
4 PFU of
C-S8c1 in the presence of FUG were analyzed. Extinction
was
observed in all cases at the second passage. Thus, the combination
of
the mutagenic base analog FU and the antiviral inhibitor G
was much
more effective than FU alone in producing viral extinction.
Systematic
extinction was observed with the standard reference
FMDV C-S8c1 clone
after two passages and with low-fitness H
clones
after only one passage in the presence of the mutagen-inhibitor
combination.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Serial passages of C-S8c1 in the absence or presence of
FU, G, or FUG. In this experiment, 9 × 105 BHK-21
cells were infected with 5 × 104 PFU of FMDV C-S8c1,
and subsequent infections were carried out with 0.1 ml of supernatant
of the previous passage (the multiplicity of infection at each passage
can be calculated from the titers shown in ordinate). The origin of
FMDV C-S8c1, conditions for mutagenic and antiviral treatment, and
those for determination of FMDV infectivity are described in Materials
and Methods. The preextinction population is indicated by an arrow.
Viral extinction was confirmed by three additional blind passages in
the absence of mutagen and inhibitor with no evidence of infectivity,
and no RT-PCR-amplifiable material was found in the supernatant of the
third passage. All titrations were done in triplicate. Standard
deviations (not included in the plots) never exceeded 15%.
|
|
Efficient extinction of MARLS in CHO cells.
MARLS displays a
130-fold-greater fitness than C-S8c1 in BHK-21 cells (59,
60), as a result of 213 serial passages in BHK-21 cells
(3). However, its fitness in CHO cells is at a much lower
level, as judged from a 10-fold-lower progeny production, than in
BHK-21 cells. Therefore, if difficulties for extinction of MARLS in
infections in the presence of FUG were due to its high fitness (Fig.
2), MARLS should manifest an increased susceptibility to FU and FUG in
infections of CHO cells. The results (Fig.
4) show that extinction of MARLS occurred
after three passages in CHO cells with FU and after two passages with
FUG, suggesting that resistance to extinction of MARLS in BHK-21 cells
was due to its high fitness in the environment provided by BHK-21 cells and not to an intrinsic property of the MARLS genome to be refractory to extinction.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
Infectivity values upon passage of FMDV MARLS in the
absence or presence of FU, G, or FUG in BHK-21 and CHO cells.
Conditions for mutagenic and antiviral treatments and for determination
of FMDV infectivity are detailed in Materials and Methods. Left panel:
FMDV MARLS was tested by infecting 9 × 105 BHK-21
cells with 5 × 104 PFU of virus, and the next
passages were carried out by infecting cells with 0.1 ml of supernatant
from the previous passage. Right panel: 9 × 105 CHO
cells were infected with 9 × 105 PFU of FMDV MARLS,
and passages were carried out as for the infections of BHK-21 cells.
The multiplicity of infection at each passage can be calculated from
the titers shown in ordinate. Preextinction populations are indicated
by arrows. Viral extinction was ascertained by three additional blind
passages in the absence of mutagen and inhibitors, with no evidence of
infectivity and RT-PCR-amplifiable material in the supernatant of the
third passage. All titrations were done in triplicate. Standard
deviations (not included in the plots) never exceeded 15%.
|
|
High-fitness virus can be extinguished with the combination of a
mutagen and two inhibitors.
The effect of FUG on FMDV C-S8c1
suggested that extinction of high-fitness MARLS in BHK-21 cells could
be favored by decreases in the viral load achieved with the combination
of two antiviral inhibitors targeted to different steps in the virus
life cycle. To test this possibility, the the effect of combination of
FU, G, and H (FUGH) on production of MARLS in BHK-21 cells was tested. The FUGH treatment resulted in a decrease of cell viability to about
20% of the untreated cells (Fig. 1). Control experiments (described in
Materials and Methods) ruled out cytotoxicity as being responsible for
the absence of viral production. The results (Fig. 4) show that a
combination of two inhibitors and a mutagen can lead to extinction of
MARLS in BHK-21 cells in three passages. In order to elucidate how
systematic the extinctions were, 47 repetitions of the passages in the
presence of FUGH were performed. In 40 cases extinction of MARLS was
obtained in the third passage and in 7 cases in the fourth passage.
Therefore, a combination of a mutagen and multiple inhibitors is
effective in promoting systematic extinction of high-fitness FMDV.
Evidence for FU-induced mutations in a preextinction population and
moderate increases in mutation frequency.
Consensus nucleotide
sequences and sequences from molecular clones were obtained from the
mixture of the supernatants of the 46 replicates of the C-S8c1FUGp1
preextinction population and C-S8c1DMEMp1 (Fig. 3). Three genomic
regions were analyzed, the ones encoding the capsid protein VP1 and the
nonstructural proteins 2C and 3D. Increases in mutation frequencies
ranged between 1.5- and 4-fold; the maximum difference was found in 3D
(Table 1) as in a previous report
(60). The number of mutations observed in the C-S8c1FUGp1
population was significantly higher than that obtained with
C-S8c1DMEMp1, as measured with the
2 test (P < 0.005 and P > 0.001;
2, 1 degree of freedom). The most abundant mutations found in the preextinction populations were the transitions A
G and U
C (Table 2), which have been associated with the
mutagenic action of FU (37, 59, 72). The number of A
G
and U
C transitions was found to be significantly higher than other
mutation types with the
2 test (P < 0.025 and P > 0.01;
2, 1 degree of
freedom). Increases were found in Shannon entropy, which is a measure
of the different types of nucleotide sequences found in the mutant
spectrum of the genomic region under study. Thus, in the three genomic
regions analyzed, the mutant spectrum of the population near extinction
was more complex than that in the corresponding control population
(Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Genetic heterogeneity in the mutant spectrum of FMDV
C-S8c1 populations subjected to one passage in DMEM or in
FUGa
|
|
 |
DISCUSSION |
The possibility of a new antiviral strategy based on increasing
the mutation rate above a threshold value (16, 34, 36, 40,
41) stems from the quasispecies dynamics of RNA virus populations (21, 57, 64). Error rates during RNA genome replication dictate that viral genomes consist of a complex mutant spectrum often dominated by a most fit genome, termed the master sequence (21, 22). Error-prone replication predicts an
error threshold relationship of the form
|
(1)
|
in which v
max is the maximum length (information
contents) that can be stably maintained in a viral genome,
0 is the selective
advantage (superiority) of the master
sequence over the mutant
spectrum, and

is the
average copying fidelity (in a scale from
0 to 1) during genome
replication; therefore (1

) is the average
error
rate (
21,
22,
57,
64). According to the error threshold
relationship, an increase in the error rate above a threshold
value
should result in the loss of information carried by the
viral genome
and therefore in a loss of infectivity. Experimental
support for this
theoretical prediction has been obtained by subjecting
vesicular
stomatitis virus, poliovirus (
10,
11,
34,
39),
and human
immunodeficiency virus type 1 (
40) to increased levels
of
mutagenesis. In the case of FMDV we showed previously that
low fitness
and reduced viral loads favored viral extinction upon
replication in
the presence of FU or 5-azacytidine or their combination
(
59,
60). Relative fitness among viral populations is conceptually
parallel to relative fitness among components of the mutant spectrum
within a viral population. The parameter
0 in equation
1
represents
the superiority of the master sequence over its mutant
spectrum,
and its value is larger the higher the relative fitness of
the
mutant distribution (
21,
22,
57). Therefore, virus
extinction
should be favored in populations with low relative fitness,
as
observed experimentally (
59,
60).
Further evidence that low fitness rather than a specific genomic
structure was responsible for virus extinction has been obtained with
infection of CHO cells with MARLS. This virus showed low fitness in
CHO, as evidenced both by a 10-fold-lower progeny production than in
BHK-21 cells and a 10-fold increase in progeny production after eight
serial passages in CHO cells (N. Pariente et al., unpublished results).
MARLS was prone to extinction with a combination of mutagen and one
inhibitor and with the mutagen alone in CHO cells but not in BHK-21
cells (compare the graphics in Fig. 4). The viral load also has a
definite influence in the adaptation (fitness increase) of viral
quasispecies. When the viral population size is small, genetic drift
and a decrease in fitness prevail (8, 23, 73, 74),
while when the replicative size of the same virus clones and
populations is large, competitive selection of increasingly adapted
mutant swarms leads to exponential increases in viral fitness
(24, 46, 47, 69).
These previous theoretical and experimental observations suggested that
a combination of a mutagenic agent and antiviral inhibitors should
increase the frequency of viral extinctions. This has indeed been
documented in the present report by using FMDV clones and populations
differing by about 106-fold in relative fitness values.
For the reference virus C-S8c1, whose relative fitness value is taken
as 1 (23, 24), a combination of FU and G resulted in 47 extinction events out of 47 trials. For MARLS, which has a
130-fold-greater fitness than C-S8c1 in BHK-21 cells, two inhibitors
were needed in combination with FU, to obtain viral extinction. This
extinction was also obtained for each of 48 trials, in fewer than five
passages. We term this occurrence systematic extinction, since chances
of virus surviving for a larger number of passages under these adverse
evolutionary conditions must be negligible. Not unexpectedly, clones
whose fitness was 103- to 104-fold-lower than
that of C-S8c1 did not survive even a single round of infection under
the same conditions.
The mutant spectrum of an FMDV C-S8c1 preextinction population,
subjected to passages in the presence of FUG, has been compared with
the mutant spectrum of a C-S8c1 population passaged in DMEM. With the
RT-PCR amplification system used, the mutation frequency values found
in the mutant spectra analyzed cannot be affected by mutations
introduced during the amplification procedures (1, 4, 59,
60). There was a significant bias toward the type of mutations
induced by FU expected from the ambiguous reading of
fluorouridine in template molecules (37, 59, 72). In the
VP1-, 2C-and 3D-coding regions, 50, 67, and 42%, respectively, of the
mutations were nonsynonymous (Table 1). The locations of amino acid
replacements in VP1, 2C, and 3D are given in Table 3. Two amino acid replacements were found
in the carboxy-terminal region of VP1 (antigenic site C
[43]) (Q191
H and H197
R). In 2C,
replacement R109
H affected the A domain, a Walker nucleoside triphosphate binding motif (49). In 3D, except for
the T365
A change in
strand 4, which is a very conserved position
among picornavirus polymerases (75), all other
replacements were located on loops linking
helices and
strands,
assuming that structural elements of poliovirus 3D (30)
coincide with those of FMDV 3D upon alignment of the two amino acid
sequences (42).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Amino acid replacements found in VP1, 2C, and 3D of the
mutant spectrum of preextinction population
C-S8c1FUGp1
|
|
One of the possible drawbacks of the combination therapy presented
herein would be the appearance of guanidine-resistant FMDV mutants due
to the action of FU. There have been several guanidine-resistant mutants of poliovirus described, and some of FMDV serotype O, and most
of them involve transition mutations presumably favored by FU
(50, 56). Nevertheless, none of the clones analyzed from a
preextinction FMDV population showed mutations described as
responsible for a guanidine-resistant phenotype, despite the fact
that FMDV replication in the presence of G alone can result in
selection of resistant mutants (55, N. Pariente et al.,
unpublished results). In case resistant mutants arose during treatments
with mutagen and inhibitors, there would be a competition between the selection of the inhibitor-resistant mutant and the mutational force
towards extinction. When such a force dominates, chances of selecting
resistant mutants diminish, and this may explain why no G-resistant
mutants were detected in the mutant spectra analyzed. The option of
using two inhibitors that act on different steps of the viral life
cycle reduces the possibility of the mutagen generating escape mutants.
The FMDV-FUG or -FUGH combination system provides a simple cell culture
model system for studying the dynamics of mutational pressure in
relation to G-resistant or H-resistant mutant generation and
efficiency of extinction. These studies are currently in progress.
The need of combination therapy with two or more inhibitors to limit
the chances of generating and selecting inhibitor-resistant mutants in
viral quasispecies has been emphasized (17, 19, 29, 33).
Early experiments suggested a more effective control of influenza virus
by a combined vaccine-antiviral strategy (32, 45, 70). In
a conceptually parallel study, ribavirin
(1-
-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) treatment prevented the appearance of neutralization-resistant mutants
of lymphocytic choriomeningitis virus in mice (58). Recent
reports (10, 11) have documented that ribavirin can be
mutagenic for poliovirus and that in this system reduction of
infectious virus production correlated with mutagenic activity of the
nucleotide analog. These results were interpreted as suggesting that
the antipoliovirus activity of ribavirin could be due to the transition
of viral replication into error catastrophe (10, 11),
although viral extinction was not observed. Ribavirin is used in the
therapy of a number of viral infections (12, 14, 48, 61).
Certainly the contribution of inhibition versus mutagenesis in the
antiviral action of ribavirin deserves further investigation. Also, the
possible contribution of inhibition of virus-specific RNA synthesis in
the extinction by FU
suggested by the reduction in viral production in
a single round of infection in the presence of FU (59,
60)
requires further investigation. Our observations on the
benefits of a combination of a mutagenic agent and one or several
antiviral inhibitors are consistent with current views on
adaptability of viral quasispecies (8, 16, 21-24, 26, 46, 47,
69). The lesser the opportunity of a virus to replicate, the
lower the chances of survival in the face of an antiviral response, be
it natural (an immune response) or induced externally (through
immune stimulation, immunotherapy, or drug administrations).
 |
ACKNOWLEDGMENTS |
We are indebted to C. Escarmís, C. M. Ruiz-Jarabo,
and E. Baranowski for helpful discussions, J. C. de la Torre for
the critical reading of the manuscript, and M. Dávila for
technical assistance.
Research in Madrid was supported by grants PM97-0060-C02-01, EU FAIR 5 PL-97-3665, and Fundación Ramón Areces. N.P. was supported
by a predoctoral fellowship from MEC (Spain), and S.S. was
supported by a predoctoral fellowship from CAM. Work in Manchester was
supported by a Sir Henry Wellcome award for innovative research (053995) to P.R.L. and E.D. and an International Research Collaboration grant from the Wellcome Trust (049862) to P.R.L. and E.D.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centro de
Biología Molecular "Severo Ochoa," Universidad
Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain. Phone:
34-91-397 8485. Fax: 34-91-397 4799. E-mail:
edomingo{at}cbm.uam.es.
Present address: Institüt für Virologie,
Universität zu Köln, 50935 Köln, Germany.
 |
REFERENCES |
| 1.
|
Arias, A.,
E. Lazaro,
C. Escarmis, and E. Domingo.
2001.
Molecular intermediates of fitness gain of an RNA virus: characterization of a mutant spectrum by biological and molecular cloning.
J. Gen. Virol.
82:1049-1060[Abstract/Free Full Text].
|
| 2.
|
Baranowski, E.,
C. M. Ruíz-Jarabo,
N. Sevilla,
D. Andreu,
E. Beck, and E. Domingo.
2000.
Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: flexibility in aphthovirus receptor usage.
J. Virol.
74:1641-1647[Abstract/Free Full Text].
|
| 3.
|
Baranowski, E.,
N. Sevilla,
N. Verdaguer,
C. M. Ruíz-Jarabo,
E. Beck, and E. Domingo.
1998.
Multiple virulence determinants of foot-and-mouth disease virus in cell culture.
J. Virol.
72:6362-6372[Abstract/Free Full Text].
|
| 4.
|
Barnes, W. M.
1994.
PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates.
Proc. Natl. Acad. Sci. USA
91:2216-2220[Abstract/Free Full Text].
|
| 5.
|
Black, D. N., and F. Brown.
1969.
Effect of actinomycin D and guanidine on the formation of a ribonucleic acid polymerase induced by foot-and-mouth-disease virus and on the replication of virus and viral ribonucleic acid.
Biochem. J.
112:317-323[Medline].
|
| 6.
|
Caplen, H.,
C. J. Peters, and D. H. Bishop.
1985.
Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development.
J. Gen. Virol.
66:2271-2277[Abstract/Free Full Text].
|
| 7.
|
Carrasco, L.
1994.
Picornavirus inhibitors.
Pharmacol. Ther.
64:215-290[CrossRef][Medline].
|
| 8.
|
Chao, L.
1990.
Fitness of RNA virus decreased by Muller's ratchet.
Nature
348:454-455[CrossRef][Medline].
|
| 9.
|
Conrad, H. E.
1998.
Heparin-binding proteins.
Academic Press, San Diego, Calif.
|
| 10.
|
Crotty, S.,
C. E. Cameron, and R. Andino.
2001.
RNA virus error catastrophe: direct molecular test by using ribavirin.
Proc. Natl. Acad. Sci. USA
98:6895-6900[Abstract/Free Full Text].
|
| 11.
|
Crotty, S.,
D. Maag,
J. J. Arnold,
W. Zhong,
J. Y. N. Lau,
Z. Hong,
R. Andino, and C. E. Cameron.
2000.
The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen.
Nat. Med.
6:1375-1379[CrossRef][Medline].
|
| 12.
|
Davis, G. L.,
R. Esteban-Mur,
V. Rustgi,
J. Hoefs,
S. C. Gordon,
C. Trepo,
M. L. Shiffman,
S. Zeuzem,
A. Craxi,
M. H. Ling, and J. Albrecht.
1998.
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
N. Engl. J. Med.
339:1493-1499[Abstract/Free Full Text].
|
| 13.
|
Dawson, W. O.
1975.
Guanidine inhibits tobacco mosaic virus RNA synthesis at two stages.
Intervirology
6:83-89[Medline].
|
| 14.
|
De Clercq, E.
1993.
Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact.
Adv. Virus Res.
42:1-55[Medline].
|
| 15.
|
de la Torre, J. C.,
E. Wimmer, and J. J. Holland.
1990.
Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus.
J. Virol.
64:664-671[Abstract/Free Full Text].
|
| 16.
|
Domingo, E.
2000.
Viruses at the edge of adaptation.
Virology
270:251-253[CrossRef][Medline].
|
| 17.
|
Domingo, E.,
C. Biebricher,
M. Eigen, and J. J. Holland.
2001.
Quasispecies and RNA virus evolution: principles and consequences.
Landes Bioscience, Austin, Tex.
|
| 18.
|
Domingo, E.,
M. Dávila, and J. Ortín.
1980.
Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus.
Gene
11:333-346[CrossRef][Medline].
|
| 19.
|
Domingo, E., and J. J. Holland.
1992.
Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents.
Genet. Eng. (N.Y.)
14:13-31.
|
| 20.
|
Eastman, P. S., and C. D. Blair.
1985.
Temperature-sensitive mutants of Japanese encephalitis virus.
J. Virol.
55:611-616[Abstract/Free Full Text].
|
| 21.
|
Eigen, M., and C. K. Biebricher.
1988.
Sequence space and quasispecies distribution, p. 211-245.
In
E. Domingo, P. Ahlquist, and J. J. Holland (ed.), RNA genetics, vol. 3. CRC Press, Boca Raton, Fla.
|
| 22.
|
Eigen, M., and P. Schuster.
1979.
The hypercycle. A principle of natural self-organization.
Springer, Berlin, Germany.
|
| 23.
|
Escarmís, C.,
M. Dávila,
N. Charpentier,
A. Bracho,
A. Moya, and E. Domingo.
1996.
Genetic lesions associated with Muller's ratchet in an RNA virus.
J. Mol. Biol.
264:255-267[CrossRef][Medline].
|
| 24.
|
Escarmís, C.,
M. Dávila, and E. Domingo.
1999.
Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet.
J. Mol. Biol.
285:495-505[CrossRef][Medline].
|
| 25.
|
Esko, J. D.,
T. E. Stewart, and W. H. Taylor.
1985.
Animal cell mutants defective in glycosaminoglycan biosynthesis.
Proc. Natl. Acad. Sci. USA
82:3197-3201[Abstract/Free Full Text].
|
| 26.
|
Flint, S. J.,
L. W. Enquist,
R. M. Krug,
V. R. Racaniello, and A. M. Skalka.
2000.
Virology. Molecular biology, pathogenesis, and control.
ASM Press, Washington D.C.
|
| 27.
|
Friedman, R. M.
1970.
Basis for variable response of arboviruses to guanidine treatment.
J. Virol.
6:628-636[Abstract/Free Full Text].
|
| 28.
|
Goodfellow, L.,
Y. Chaudhry,
A. Richardson,
J. Meredith,
J. W. Almond,
W. Barclay, and D. J. Evans.
2000.
Identification of a cis-acting replication element within the poliovirus coding region.
J. Virol.
74:4590-4600[Abstract/Free Full Text].
|
| 29.
|
Hammer, S. M.,
K. E. Squires,
M. D. Hughes,
J. M. Grimes,
L. M. Demeter,
J. S. Currier,
J. J. Eron, Jr.,
J. E. Feinberg,
H. H. Balfour, Jr.,
L. R. Deyton,
J. A. Chodakewitz, and M. A. Fischl.
1997.
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
N. Engl. J. Med.
337:725-733[Abstract/Free Full Text].
|
| 30.
|
Hansen, J.,
A. M. Long, and S. Schultz.
1997.
Structure of the RNA-dependent RNA polymerase of poliovirus.
Structure
15:1109-1122[CrossRef].
|
| 31.
|
Haspel, M. V.,
P. W. Lampert, and M. B. Oldstone.
1978.
Temperature-sensitive mutants of mouse hepatitis virus produce a high incidence of demyelination.
Proc. Natl. Acad. Sci. USA
75:4033-4036[Abstract/Free Full Text].
|
| 32.
|
Hayden, F. G.
1986.
Combinations of antiviral agents for treatment of influenza virus infections.
J. Antimicrob. Chemother.
18:177-183[Abstract/Free Full Text].
|
| 33.
|
Ho, D. D.
1998.
Toward HIV eradication or remission: the tasks ahead.
Science
280:1866-1867[Abstract/Free Full Text].
|
| 34.
|
Holland, J. J.,
E. Domingo,
J. C. de la Torre, and D. A. Steinhauer.
1990.
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis.
J. Virol.
64:3960-3962[Abstract/Free Full Text].
|
| 35.
|
Jackson, T.,
F. M. Ellard,
R. A. Ghazaleh,
S. M. Brookes,
W. E. Blakemore,
A. H. Corteyn,
D. L. Stuart,
J. W. Newman, and A. M. King.
1996.
Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate.
J. Virol.
70:5282-5287[Abstract/Free Full Text].
|
| 36.
|
Ji, J.,
J. S. Hoffmann, and L. Loeh.
1994.
Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis.
Nucleic Acids Res.
22:47-52[Abstract/Free Full Text].
|
| 37.
|
Kunz, B. A., and S. E. Kohalmi.
1991.
Modulation of mutagenesis by deoxyribonucleotide levels.
Annu. Rev. Genet.
25:339-359[CrossRef][Medline].
|
| 38.
|
Lea, S.,
J. Hernández,
W. Blakemore,
E. Brocchi,
S. Curry,
E. Domingo,
E. Fry,
R. Abu-Ghazaleh,
A. King,
J. Newman,
D. Stuart, and M. G. Mateu.
1994.
The structure and antigenicity of a type C foot-and-mouth disease virus.
Structure
2:123-139[Medline].
|
| 39.
|
Lee, C. H.,
D. L. Gilbertson,
I. S. Novella,
R. Huerta,
E. Domingo, and J. J. Holland.
1997.
Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus.
J. Virol.
71:3636-3640[Abstract].
|
| 40.
|
Loeb, L. A.,
J. M. Essigmann,
F. Kazazi,
J. Zhang,
K. D. Rose, and J. I. Mullins.
1999.
Lethal mutagenesis of HIV with mutagenic nucleoside analogs.
Proc. Natl. Acad. Sci. USA
96:1492-1497[Abstract/Free Full Text].
|
| 41.
|
Loeb, L. A., and J. I. Mullins.
2000.
Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs.
AIDS Res. Hum. Retrovir.
13:1-3.
|
| 42.
|
Martínez-Salas, E.,
J. Ortín, and E. Domingo.
1985.
Sequence of the viral replicase gene from foot-and-mouth disease virus C1-Santa Pau (C-S8).
Gene
35:55-61[CrossRef][Medline].
|
| 43.
|
Mateu, M. G.
1995.
Antibody recognition of picornaviruses and escape from neutralization: a structural view.
Virus Res.
38:1-24[CrossRef][Medline].
|
| 44.
|
Mateu, M. G.,
M. A. Martinez,
L. Capucci,
D. Andreu,
E. Giralt,
F. Sobrino,
E. Brocchi, and E. Domingo.
1990.
A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C.
J. Gen. Virol.
71:629-637[Abstract/Free Full Text].
|
| 45.
|
Murphy, B. R., and R. G. Webster.
1996.
Orthomyxoviruses, p. 1397-1445.
In
B. M. Fields (ed.), Fields virology. Lippincott-Ravel Publishers, Philadelphia, Pa.
|
| 46.
|
Novella, I. S.,
E. A. Duarte,
S. F. Elena,
A. Moya,
E. Domingo, and J. J. Holland.
1995.
Exponential increases of RNA virus fitness during large population transmissions.
Proc. Natl. Acad. Sci. USA
92:5841-5844[Abstract/Free Full Text].
|
| 47.
|
Novella, I. S.,
C. L. Hershey,
C. Escarmis,
E. Domingo, and J. J. Holland.
1999.
Lack of evolutionary stasis during alternating replication of an arbovirus in insect and mammalian cells.
J. Mol. Biol.
287:459-465[CrossRef][Medline].
|
| 48.
|
Pawlotsky, J. M.
2000.
Hepatitis C virus resistance to antiviral therapy.
Hepatology
32:889-896[CrossRef][Medline].
|
| 49.
|
Pfister, T., and E. Wimmer.
1999.
Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication.
J. Biol. Chem.
274:6992-7001[Abstract/Free Full Text].
|
| 50.
|
Pincus, S. E., and E. Wimmer.
1986.
Production of guanidine-resistant and -dependent poliovirus mutants from cloned cDNA: mutations in polypeptide 2C are directly responsible for altered guanidine sensitivity.
J. Virol.
60:793-796[Abstract/Free Full Text].
|
| 51.
|
Pringle, C. R.
1970.
Genetic characteristics of conditional lethal mutants of vesicular stomatitis virus induced by 5-fluorouracil, 5-azacytidine, and ethyl methane sulfonate.
J. Virol.
5:559-567[Abstract/Free Full Text].
|
| 52.
|
Righstel, W. A.,
J. R. Dice,
R. J. McAlpine,
E. A. Timm,
I. W. J. McLean,
G. J. Dixon, and F. M. J. Schabel.
1961.
Antiviral effect of guanidine.
Science
134:558-559[Abstract/Free Full Text].
|
| 53.
|
Riviere, Y., and M. B. A. Oldstone.
1986.
Genetic reassortants of lymphocytic choriomeningitis virus: unexpected disease and mechanism of pathogenesis.
J. Virol.
59:363-368[Abstract/Free Full Text].
|
| 54.
|
Sa-Carvalho, D.,
E. Rieder,
B. Baxt,
R. Rodarte,
A. Tanuri, and P. W. Mason.
1997.
Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle.
J. Virol.
71:5115-5123[Abstract].
|
| 55.
|
Saunders, K., and A. M. King.
1982.
Guanidine-resistant mutants of aphthovirus induce the synthesis of an altered nonstructural polypeptide, P34.
J. Virol.
42:389-394[Abstract/Free Full Text].
|
| 56.
|
Saunders, K.,
A. M. King,
D. McCahon,
J. W. Newman,
W. R. Slade, and S. Forss.
1985.
Recombination and oligonucleotide analysis of guanidine-resistant foot-and-mouth disease virus mutants.
J. Virol.
56:921-929[Abstract/Free Full Text].
|
| 57.
|
Schuster, P., and P. F. Stadler.
1999.
Nature and evolution of early replicons, p. 1-24.
In
E. Domingo, R. G. Webster, and J. J. Holland (ed.), Origin and evolution of viruses. Academic Press, San Diego, Calif.
|
| 58.
|
Seiler, P.,
B. M. Senn,
P. Klenerman,
U. Kalinke,
H. Hengartner, and R. M. Zinkernagel.
2000.
Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.
J. Virol.
74:5896-5901[Abstract/Free Full Text].
|
| 59.
|
Sierra, S.
2001.
Caracterización de la respuesta del virus de la fiebre aftosa a mutagénesis química. Tesis Doctoral. Ph.D. Thesis.
Universidad Autónoma de Madrid, Madrid, Spain.
|
| 60.
|
Sierra, S.,
M. Dávila,
P. R. Lowenstein, and E. Domingo.
2000.
Response of foot-and-mouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity.
J. Virol.
74:8316-8323[Abstract/Free Full Text].
|
| 61.
|
Smith, R. A., and W. Kirkpatrick.
1980.
Ribavirin: a broad spectrum antiviral agent.
Academic Press, Inc., New York, N.Y.
|
| 62.
|
Sobrino, F.,
M. Dávila,
J. Ortín, and E. Domingo.
1983.
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture.
Virology
128:310-318[CrossRef][Medline].
|
| 63.
|
Sobrino, F.,
M. Sáiz,
M. A. Jiménez-Clavero,
J. L. Núñez,
M. F. Rosas,
E. Baranowski, and V. Ley.
2001.
Foot-and-mouth disease virus: a long known virus, but a current threat.
Vet. Res.
32:1-30[CrossRef][Medline].
|
| 64.
|
Swetina, J., and P. Schuster.
1982.
Self-replication with errors. A model for polynucleotide replication.
Biophys. Chem.
16:329-345[CrossRef][Medline].
|
| 65.
|
Toja, M.,
C. Escarmis, and E. Domingo.
1999.
Genomic nucleotide sequence of a foot-and-mouth disease virus clone and its persistent derivatives. Implications for the evolution of viral quasispecies during a persistent infection.
Virus Res.
64:161-171[CrossRef][Medline].
|
| 66.
|
Toyoda, H.,
M. Kohara,
Y. Kataoka,
T. Suganuma,
T. Omata,
N. Imura, and A. Nomoto.
1984.
Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.
J. Mol. Biol.
174:561-585[CrossRef][Medline].
|
| 67.
|
Varma, J. P.
1968.
Inhibition of tobacco necrosis virus by guanidine carbonate.
Virology
36:305-308[CrossRef][Medline].
|
| 68.
|
Volkenstein, M. V.
1994.
Physical approaches to biological evolution.
Springer-Verlag, Berlin, Germany.
|
| 69.
|
Weaver, S. C.,
A. C. Brault,
W. Kang, and J. J. Holland.
1999.
Genetic and fitness changes accompanying adaptation of an arbovirus to vertebrate and invertebrate cells.
J. Virol.
73:4316-4326[Abstract/Free Full Text].
|
| 70.
|
Webster, R. G.,
Y. Kawaoka, and W. J. Bean.
1986.
Vaccination as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus.
J. Antimicrob. Chemother.
18:157-164.
|
| 71.
|
Wittmann, H. G., and B. Wittmann-Liebold.
1966.
Protein chemical studies of two RNA viruses and their mutants.
Cold Spring Harbor Symp. Quant. Biol.
31:163-172[Abstract/Free Full Text].
|
| 72.
|
Yu, H.,
R. Eritja,
L. B. Bloom, and M. F. Goodman.
1993.
Ionization of bromouracil and fluorouracil stimulates base mispairing frequencies with guanine.
J. Biol. Chem.
268:15935-15943[Abstract/Free Full Text].
|
| 73.
|
Yuste, E.,
C. Lopez-Galindez, and E. Domingo.
2000.
Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1.
J. Virol.
74:9546-9552[Abstract/Free Full Text].
|
| 74.
|
Yuste, E.,
S. Sánchez-Palomino,
C. Casado,
E. Domingo, and C. López-Galíndez.
1999.
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events.
J. Virol.
73:2745-2751[Abstract/Free Full Text].
|
| 75.
|
Zimmern, D.
1988.
Evolution of RNA viruses, p. 211-240.
In
E. Domingo, J. J. Holland, and P. Ahlquist (ed.), RNA Genetics, vol. 2. CRC Press Inc., Boca Raton, Fla.
|
Journal of Virology, October 2001, p. 9723-9730, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9723-9730.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chen, P., Shakhnovich, E. I.
(2009). Lethal Mutagenesis in Viruses and Bacteria. Genetics
183: 639-650
[Abstract]
[Full Text]
-
Sanz-Ramos, M., Diaz-San Segundo, F., Escarmis, C., Domingo, E., Sevilla, N.
(2008). Hidden Virulence Determinants in a Viral Quasispecies In Vivo. J. Virol.
82: 10465-10476
[Abstract]
[Full Text]
-
Bull, J. J., Wilke, C. O.
(2008). Lethal Mutagenesis of Bacteria. Genetics
180: 1061-1070
[Abstract]
[Full Text]
-
Chung, D.-H., Sun, Y., Parker, W. B., Arterburn, J. B., Bartolucci, A., Jonsson, C. B.
(2007). Ribavirin Reveals a Lethal Threshold of Allowable Mutation Frequency for Hantaan Virus. J. Virol.
81: 11722-11729
[Abstract]
[Full Text]
-
Carrillo, C., Lu, Z., Borca, M. V., Vagnozzi, A., Kutish, G. F., Rock, D. L.
(2007). Genetic and Phenotypic Variation of Foot-and-Mouth Disease Virus during Serial Passages in a Natural Host. J. Virol.
81: 11341-11351
[Abstract]
[Full Text]
-
Graci, J. D., Harki, D. A., Korneeva, V. S., Edathil, J. P., Too, K., Franco, D., Smidansky, E. D., Paul, A. V., Peterson, B. R., Brown, D. M., Loakes, D., Cameron, C. E.
(2007). Lethal Mutagenesis of Poliovirus Mediated by a Mutagenic Pyrimidine Analogue. J. Virol.
81: 11256-11266
[Abstract]
[Full Text]
-
Ferrer-Orta, C., Arias, A., Perez-Luque, R., Escarmis, C., Domingo, E., Verdaguer, N.
(2007). Sequential structures provide insights into the fidelity of RNA replication. Proc. Natl. Acad. Sci. USA
104: 9463-9468
[Abstract]
[Full Text]
-
Sierra, M., Airaksinen, A., Gonzalez-Lopez, C., Agudo, R., Arias, A., Domingo, E.
(2007). Foot-and-Mouth Disease Virus Mutant with Decreased Sensitivity to Ribavirin: Implications for Error Catastrophe. J. Virol.
81: 2012-2024
[Abstract]
[Full Text]
-
Suzuki, T., Moriyama, K., Otsuka, C., Loakes, D., Negishi, K.
(2006). Template properties of mutagenic cytosine analogues in reverse transcription. Nucleic Acids Res
34: 6438-6449
[Abstract]
[Full Text]
-
Summers, J., Litwin, S.
(2006). Examining The Theory of Error Catastrophe. J. Virol.
80: 20-26
[Full Text]
-
Grande-Perez, A., Gomez-Mariano, G., Lowenstein, P. R., Domingo, E.
(2005). Mutagenesis-Induced, Large Fitness Variations with an Invariant Arenavirus Consensus Genomic Nucleotide Sequence. J. Virol.
79: 10451-10459
[Abstract]
[Full Text]
-
Ferrer-Orta, C., Arias, A., Perez-Luque, R., Escarmis, C., Domingo, E., Verdaguer, N.
(2004). Structure of Foot-and-Mouth Disease Virus RNA-dependent RNA Polymerase and Its Complex with a Template-Primer RNA. J. Biol. Chem.
279: 47212-47221
[Abstract]
[Full Text]
-
Garcia-Arriaza, J., Manrubia, S. C., Toja, M., Domingo, E., Escarmis, C.
(2004). Evolutionary Transition toward Defective RNAs That Are Infectious by Complementation. J. Virol.
78: 11678-11685
[Abstract]
[Full Text]
-
Gonzalez-Lopez, C., Arias, A., Pariente, N., Gomez-Mariano, G., Domingo, E.
(2004). Preextinction Viral RNA Can Interfere with Infectivity. J. Virol.
78: 3319-3324
[Abstract]
[Full Text]
-
Lazaro, E., Escarmis, C., Perez-Mercader, J., Manrubia, S. C., Domingo, E.
(2003). Resistance of virus to extinction on bottleneck passages: Study of a decaying and fluctuating pattern of fitness loss. Proc. Natl. Acad. Sci. USA
100: 10830-10835
[Abstract]
[Full Text]
-
Pariente, N., Airaksinen, A., Domingo, E.
(2003). Mutagenesis versus Inhibition in the Efficiency of Extinction of Foot-and-Mouth Disease Virus. J. Virol.
77: 7131-7138
[Abstract]
[Full Text]
-
Grande-Perez, A., Sierra, S., Castro, M. G., Domingo, E., Lowenstein, P. R.
(2002). From the Cover: Molecular indetermination in the transition to error catastrophe: Systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. USA
99: 12938-12943
[Abstract]
[Full Text]
-
Lazaro, E., Escarmis, C., Domingo, E., Manrubia, S. C.
(2002). Modeling Viral Genome Fitness Evolution Associated with Serial Bottleneck Events: Evidence of Stationary States of Fitness. J. Virol.
76: 8675-8681
[Abstract]
[Full Text]